purpose present outcomes therapy proton beam irradiation patients invasive bladder cancer methods materials patients transitional cell carcinoma urinary bladder underwent transurethral resection bladder tumors followed pelvic irradiation combined chemotherapy methotrexate cisplatin completion treatments patients evaluated transurethral resection biopsy patients residual tumor received proton irradiation boost primary sites patients demonstrating residual tumors underwent radical cystectomy results NUMBER patients NUMBER NUMBER free residual tumor time consequently proton beam therapy applied remaining NUMBER patients presenting residual tumors underwent radical cystectomy NUMBER patients treated proton beam therapy NUMBER experienced recurrence median time NUMBER years local recurrences distant metastases NUMBER NUMBER patients respectively situations NUMBER overall survival rates NUMBER NUMBER NUMBER respectively local control rates NUMBER NUMBER respectively patients treated proton beam therapy toxicities grade observed NUMBER patients hematologic toxicities NUMBER pulmonary thrombosis NUMBER hemorrhagic cystitis NUMBER conclusions present regimen invasive bladder cancer feasible effective proton beam therapy improve local control facilitate bladder preservation bladder preserving ct2 3n0m0 x ray intra arterial evaluation follow NUMBER year disease free cause specific NUMBER year bladder preservation therapy related NUMBER NUMBER bladder preserving